Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.coviro.2021.06.004 http://scihub22266oqcxt.onion/10.1016/j.coviro.2021.06.004 34218010!8214175!34218010     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Curr+Opin+Virol 2021 ; 49 (ä): 183-193 Nephropedia Template TP {{tp|p=34218010|t=2021. Progress and pitfalls of a year of drug repurposing screens against COVID-19 |pdf=|usr=}}{{34218010}} gab.com Text Progress and pitfalls of a year of drug repurposing screens against COVID-19 JO: Curr Opin Virol http://www.kidney.de/pget.php?&tw=1&pmid=34218010 #FOAvip Near the end of 2019, a new betacoronavirus started to efficiently transmit between humans, resulting in the current COVID-19 pandemic. Unprecedented worldwide efforts were made to identify and repurpose antiviral therapeutics from collections of approved drugs and known bioactive compounds. Typical pitfalls of this approach (promiscuous/cytotoxic compounds leading to false positives), combined with bypassing antiviral drug development parameters due to urgency have resulted in often disappointing outcomes. A flood of publications, press-releases, and media posts, created confusion in the general public and sometime mobilized precious resources for clinical trials with minimal prospect of success. Breakthroughs have been made, not in the laboratory but in the clinic, resulting from the empiric identification of mitigators of clinical signs such as the discovery of improved disease management through immunomodulators. This opinion piece will aim to capture some of the lessons that we believe the COVID-19 pandemic has taught about drug repurposing screens. Twit Text FOAVip Progress and pitfalls of a year of drug repurposing screens against COVID-19 ????Curr Opin Virol http://www.kidney.de/pget.php?&tw=1&pmid=34218010 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34218010 #FOAvip English Wikipedia <ref>{{Cite pmid|34218010}}</ref> Progress and pitfalls of a year of drug repurposing screens against COVID-19 #MMPMID34218010 Sourimant J; Aggarwal M; Plemper RK Curr Opin Virol 2021[Aug]; 49 (ä): 183-193 PMID34218010show ga Near the end of 2019, a new betacoronavirus started to efficiently transmit between humans, resulting in the current COVID-19 pandemic. Unprecedented worldwide efforts were made to identify and repurpose antiviral therapeutics from collections of approved drugs and known bioactive compounds. Typical pitfalls of this approach (promiscuous/cytotoxic compounds leading to false positives), combined with bypassing antiviral drug development parameters due to urgency have resulted in often disappointing outcomes. A flood of publications, press-releases, and media posts, created confusion in the general public and sometime mobilized precious resources for clinical trials with minimal prospect of success. Breakthroughs have been made, not in the laboratory but in the clinic, resulting from the empiric identification of mitigators of clinical signs such as the discovery of improved disease management through immunomodulators. This opinion piece will aim to capture some of the lessons that we believe the COVID-19 pandemic has taught about drug repurposing screens. |*COVID-19 Drug Treatment[MESH] |*Drug Repositioning[MESH] |Antiviral Agents/pharmacology/*therapeutic use[MESH] |COVID-19/epidemiology[MESH] |Disease Management[MESH] |Drug Evaluation, Preclinical[MESH] |Humans[MESH] |SARS-CoV-2/drug effects[MESH]Progress and pitfalls of a year of drug repurposing screens against CO(epmc).pdf DeepDyve Pubget Overpricing